Search Results - "Leverenz, James B."

The neurobiological basis of cognitive impairment in Parkinson's disease by Halliday, Glenda M., Leverenz, James B., Schneider, Jay S., Adler, Charles H.

“…ABSTRACT The recent formalization of clinical criteria for Parkinson's disease with dementia (PDD) codifies many studies on this topic, including those…”
Get full text

TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer's disease mouse models by Jay, Taylor R, Miller, Crystal M, Cheng, Paul J, Graham, Leah C, Bemiller, Shane, Broihier, Margaret L, Xu, Guixiang, Margevicius, Daniel, Karlo, J Colleen, Sousa, Gregory L, Cotleur, Anne C, Butovsky, Oleg, Bekris, Lynn, Staugaitis, Susan M, Leverenz, James B, Pimplikar, Sanjay W, Landreth, Gary E, Howell, Gareth R, Ransohoff, Richard M, Lamb, Bruce T

“…Variants in triggering receptor expressed on myeloid cells 2 (TREM2) confer high risk for Alzheimer's disease (AD) and other neurodegenerative diseases…”
Get full text

Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases by Espay, Alberto J, Vizcarra, Joaquin A, Marsili, Luca, Lang, Anthony E, Simon, David K, Merola, Aristide, Josephs, Keith A, Fasano, Alfonso, Morgante, Francesca, Savica, Rodolfo, Greenamyre, J Timothy, Cambi, Franca, Yamasaki, Tritia R, Tanner, Caroline M, Gan-Or, Ziv, Litvan, Irene, Mata, Ignacio F, Zabetian, Cyrus P, Brundin, Patrik, Fernandez, Hubert H, Standaert, David G, Kauffman, Marcelo A, Schwarzschild, Michael A, Sardi, S Pablo, Sherer, Todd, Perry, George, Leverenz, James B

“…The gold standard for a definitive diagnosis of Parkinson disease (PD) is the pathologic finding of aggregated α-synuclein into Lewy bodies and for Alzheimer…”
Get full text

Network medicine links SARS-CoV-2/COVID-19 infection to brain microvascular injury and neuroinflammation in dementia-like cognitive impairment by Zhou, Yadi, Xu, Jielin, Hou, Yuan, Leverenz, James B, Kallianpur, Asha, Mehra, Reena, Liu, Yunlong, Yu, Haiyuan, Pieper, Andrew A, Jehi, Lara, Cheng, Feixiong

“…Dementia-like cognitive impairment is an increasingly reported complication of SARS-CoV-2 infection. However, the underlying mechanisms responsible for this…”
Get full text

Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis by Irwin, David J, Dr, Grossman, Murray, MD, Weintraub, Daniel, MD, Hurtig, Howard I, MD, Duda, John E, MD, Xie, Sharon X, PhD, Lee, Edward B, MD, Van Deerlin, Vivianna M, MD, Lopez, Oscar L, MD, Kofler, Julia K, MD, Nelson, Peter T, MD, Jicha, Gregory A, MD, Woltjer, Randy, MD, Quinn, Joseph F, MD, Kaye, Jeffery, MD, Leverenz, James B, MD, Tsuang, Debby, MD, Longfellow, Katelan, MD, Yearout, Dora, BS, Kukull, Walter, PhD, Keene, C Dirk, MD, Montine, Thomas J, MD, Zabetian, Cyrus P, MD, Trojanowski, John Q, MD

“…Summary Background Great heterogeneity exists in survival and the interval between onset of motor symptoms and dementia symptoms across synucleinopathies. We…”
Get full text

Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria by Dickson, Dennis W, MD, Braak, Heiko, MD, Duda, John E, MD, Duyckaerts, Charles, MD, Gasser, Thomas, MD, Halliday, Glenda M, PhD, Hardy, John, PhD, Leverenz, James B, MD, Del Tredici, Kelly, MD, Wszolek, Zbigniew K, MD, Litvan, Irene, MD

“…Summary To date, there have been few systematic attempts to provide a standard operating procedure for the neuropathological diagnosis of Parkinson's disease…”
Get full text

Profile of Cognitive Impairment in Parkinson's Disease by Watson, G. Stennis, Leverenz, James B.

“…Cognitive impairment (CI) is a common nonmotor complication of Parkinson's disease (PD), and is associated with significant disability for patients and burden…”
Get full text

Neuropathologic substrates of Parkinson disease dementia by Irwin, David J., White, Matthew T., Toledo, Jon B., Xie, Sharon X., Robinson, John L., Van Deerlin, Vivianna, Lee, Virginia M.-Y., Leverenz, James B., Montine, Thomas J., Duda, John E., Hurtig, Howard I., Trojanowski, John Q.

“…Objective: A study was undertaken to examine the neuropathological substrates of cognitive dysfunction and dementia in Parkinson disease (PD). Methods: One…”
Get full text

Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: Phase 3 study by Sabri, Osama, Sabbagh, Marwan N, Seibyl, John, Barthel, Henryk, Akatsu, Hiroyasu, Ouchi, Yasuomi, Senda, Kohei, Murayama, Shigeo, Ishii, Kenji, Takao, Masaki, Beach, Thomas G, Rowe, Christopher C, Leverenz, James B, Ghetti, Bernardino, Ironside, James W, Catafau, Ana M, Stephens, Andrew W, Mueller, Andre, Koglin, Norman, Hoffmann, Anja, Roth, Katrin, Reininger, Cornelia, Schulz-Schaeffer, Walter J

“…Abstract Background Evaluation of brain β-amyloid by positron emission tomography (PET) imaging can assist in the diagnosis of Alzheimer disease (AD) and other…”
Get full text

Metabolic syndrome biomarkers relate to rate of cognitive decline in MCI and dementia stages of Alzheimer's disease by Pillai, Jagan A, Bena, James, Bekris, Lynn, Kodur, Nandan, Kasumov, Takhar, Leverenz, James B, Kashyap, Sangeeta R

“…The relationship between biomarkers of metabolic syndrome and insulin resistance, plasma triglyceride/HDL cholesterol (TG/HDL-C) ratio, on the rate of…”
Get full text

DNA methylation of TOMM40-APOE-APOC2 in Alzheimer's disease by Shao, Yvonne, Shaw, McKenzie, Todd, Kaitlin, Khrestian, Maria, D'Aleo, Giana, Barnard, P John, Zahratka, Jeff, Pillai, Jagan, Yu, Chang-En, Keene, C Dirk, Leverenz, James B, Bekris, Lynn M

“…The apolipoprotein E (APOE) ε4 allele is the major genetic risk factor for Alzheimer's disease (AD). Multiple regulatory elements, spanning the extended…”
Get full text

Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression by Shi, Min, Bradner, Joshua, Hancock, Aneeka M., Chung, Kathryn A., Quinn, Joseph F., Peskind, Elaine R., Galasko, Douglas, Jankovic, Joseph, Zabetian, Cyrus P., Kim, Hojoong M., Leverenz, James B., Montine, Thomas J., Ginghina, Carmen, Kang, Un Jung, Cain, Kevin C., Wang, Yu, Aasly, Jan, Goldstein, David, Zhang, Jing

“…Objective: There is a clear need to develop biomarkers for Parkinson disease (PD) diagnosis, differential diagnosis of Parkinsonian disorders, and monitoring…”
Get full text

Plasma apolipoprotein A1 as a biomarker for Parkinson disease by Qiang, Judy K., Wong, Yvette C., Siderowf, Andrew, Hurtig, Howard I., Xie, Sharon X., Lee, Virginia M.-Y., Trojanowski, John Q., Yearout, Dora, B. Leverenz, James, Montine, Thomas J., Stern, Matt, Mendick, Susan, Jennings, Danna, Zabetian, Cyrus, Marek, Ken, Chen-Plotkin, Alice S.

“…Objective To identify plasma‐based biomarkers for Parkinson disease (PD) risk. Methods In a discovery cohort of 152 PD patients, plasma levels of 96 proteins…”
Get full text

CDC7 inhibition blocks pathological TDP-43 phosphorylation and neurodegeneration by Liachko, Nicole F., McMillan, Pamela J., Guthrie, Chris R., Bird, Thomas D., Leverenz, James B., Kraemer, Brian C.

“…Objective Kinase hyperactivity occurs in both neurodegenerative disease and cancer. Lesions containing hyperphosphorylated aggregated TDP‐43 characterize…”
Get full text

AlzGPS: a genome-wide positioning systems platform to catalyze multi-omics for Alzheimer's drug discovery by Zhou, Yadi, Fang, Jiansong, Bekris, Lynn M, Kim, Young Heon, Pieper, Andrew A, Leverenz, James B, Cummings, Jeffrey, Cheng, Feixiong

“…Recent DNA/RNA sequencing and other multi-omics technologies have advanced the understanding of the biology and pathophysiology of AD, yet there is still a…”
Get full text

Correlation between brain volume and retinal photoreceptor outer segment volume in normal aging and neurodegenerative diseases by Uchida, Atsuro, Pillai, Jagan A, Bermel, Robert, Jones, Stephen E, Fernandez, Hubert, Leverenz, James B, Srivastava, Sunil K, Ehlers, Justis P

“…To investigate the association between outer retinal layer metrics, including photoreceptor outer segment volume, on spectral-domain optical coherence…”
Get full text

Artificial intelligence framework identifies candidate targets for drug repurposing in Alzheimer's disease by Fang, Jiansong, Zhang, Pengyue, Wang, Quan, Chiang, Chien-Wei, Zhou, Yadi, Hou, Yuan, Xu, Jielin, Chen, Rui, Zhang, Bin, Lewis, Stephen J, Leverenz, James B, Pieper, Andrew A, Li, Bingshan, Li, Lang, Cummings, Jeffrey, Cheng, Feixiong

“…Genome-wide association studies (GWAS) have identified numerous susceptibility loci for Alzheimer's disease (AD). However, utilizing GWAS and multi-omics data…”
Get full text

Pathological correlates of dementia in a longitudinal, population-based sample of aging by Sonnen, Joshua A., Larson, Eric B., Crane, Paul K., Haneuse, Sebastien, Li, Ge, Schellenberg, Gerald D., Craft, Suzanne, Leverenz, James B., Montine, Thomas J.

“…Objective Previously published community‐ or population‐based studies of brain aging and dementia with autopsy were restricted to a single sex, a single ethnic…”
Get full text

The tau tubulin kinases TTBK1/2 promote accumulation of pathological TDP-43 by Liachko, Nicole F, McMillan, Pamela J, Strovas, Timothy J, Loomis, Elaine, Greenup, Lynne, Murrell, Jill R, Ghetti, Bernardino, Raskind, Murray A, Montine, Thomas J, Bird, Thomas D, Leverenz, James B, Kraemer, Brian C

“…Pathological aggregates of phosphorylated TDP-43 characterize amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD-TDP), two…”
Get full text

TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis by Van Deerlin, Vivianna M, MD, Leverenz, James B, MD, Bekris, Lynn M, PhD, Bird, Thomas D, MD, Yuan, Wuxing, MS, Elman, Lauren B, MD, Clay, Dana, MS, Wood, Elisabeth McCarty, MS, Chen-Plotkin, Alice S, MD, Martinez-Lage, Maria, MD, Steinbart, Ellen, MA, McCluskey, Leo, MD, Grossman, Murray, MD, Neumann, Manuela, MD, Wu, I-Lin, MS, Yang, Wei-Shiung, MD, Kalb, Robert, MD, Galasko, Douglas R, MD, Montine, Thomas J, MD, Trojanowski, John Q, MD, Lee, Virginia M-Y, PhD, Schellenberg, Gerard D, PhD, Yu, Chang-En, PhD

“…Summary Background TDP-43 is a major component of the ubiquitinated inclusions that characterise amyotrophic lateral sclerosis (ALS) and frontotemporal lobar…”
Get full text